Back to results
US 2010/0075916 A1Published application
Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
AssigneeAuspex Pharmaceuticals, Inc.
InventorsThomas G. Gant, Sepehr Sarshar, Manouchehr M. Shahbaz
Life of this patent
Estimating the term…
Abstract
The present invention relates to new substituted quinazoline inhibitors of vascular endothelial growth factor receptor tyrosine kinase, epidermal growth factor receptor tyrosine kinase, and/or REarranged during Transfection tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.
Claims51
A compound of structural Formula I
- or a salt thereof, wherein:
- R1-R10, R12-R22, R24-R26, are independently selected from the group consisting of hydrogen and deuterium;
- R11 is selected from the group consisting of hydrogen, deuterium, and
- R23 is selected from the group consisting of hydrogen, deuterium, and
- and
- at least one of R1-R26 is deuterium.
3 more elements
A compound of Formula II
- or a pharmaceutical salt thereof;
- wherein:
- each Z is independently selected from hydrogen or deuterium;
- each R is selected from —CH3, —CH2D, —CHD2, and —CD3;
- and
- when each R is —CH3;
- at least one Z is deuterium.
4 more elements
A compound of Formula A
- or a pharmaceutically acceptable salt thereof;
- wherein:
- each Z is independently selected from hydrogen and deuterium;
- each R is selected from —CH3, —CH2D, —CHD2, and CD3;
- and
- when each R is —CH3 at least one Z is deuterium.
3 more elements
Dependencies are inferred from the claim text.